Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord

[Display omitted] Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), A...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pharmacological research Ročník 143; s. 86 - 96
Hlavní autoři:	Kumar, Manish, Kulshrestha, Ritu, Singh, Nirmal, Jaggi, Amteshwar Singh
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier Ltd 01.05.2019
Témata:	Alzheimer’s disease Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Brain Humans Imatinib Imatinib Mesylate - pharmacology Imatinib Mesylate - therapeutic use Multiple sclerosis Nervous System Diseases - drug therapy Nervous System Diseases - metabolism Parkinson disease Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Spinal Cord Spinal cord injury Stroke Tyrosine kinase NF-κβ Multiple sclerosis BBB FLT3 Parkinson disease Spinal cord injury LPS Aβ Tyrosine kinase AICD PDGFR t-PA Imatinib Stroke AD MOG Alzheimer’s disease c-kit EAE c-Abl MAPK IL-6 MMP β-CTF APC TNF-α Lck ARG AβPP GSAP MPTP HEK cells
ISSN:	1043-6618, 1096-1186, 1096-1186
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!